Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) shares fell 16.7% on Monday . The stock traded as low as C$0.31 and last traded at C$0.35. 86,380 shares changed hands during trading, an increase of 542% from the average session volume of 13,464 shares. The stock had previously closed at C$0.42.
Aptose Biosciences Trading Down 21.4 %
The firm has a 50 day simple moving average of C$0.41 and a 200 day simple moving average of C$0.65. The company has a current ratio of 0.80, a quick ratio of 5.41 and a debt-to-equity ratio of 670.80. The firm has a market capitalization of C$5.98 million, a PE ratio of -0.06 and a beta of 1.36.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- How to Calculate Return on Investment (ROI)
- Time to Board Carnival Cruise Lines’ Stock Price Rally
- What is the Nikkei 225 index?
- Is Warner Bros. Discovery Stock a Buy After Recent Drop?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
